Cargando…

Second Generation Drug-Eluting Stents for Endovascular Treatment of Ostial Vertebral Artery Stenosis: A Single Center Experience

Objective: To report a single-center experience using drug-eluting balloon mounted stents (DES) for endovascular treatment of atherosclerotic ostial vertebral artery stenosis (OVAS). Background: Posterior circulation is affected in up to 25% of strokes, 20% of them resulting from atherosclerotic OVA...

Descripción completa

Detalles Bibliográficos
Autores principales: Ortega-Gutierrez, Santiago, Lopez, Gloria V., Edgell, Randall C., Mendez, Aldo A., Dandapat, Sudeepta, Roa, Jorge A., Zevallos, Cynthia B., Holcombe, Andrea L., Hasan, David, Derdeyn, Colin P., Rossen, James, Samaniego, Edgar A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6646661/
https://www.ncbi.nlm.nih.gov/pubmed/31379708
http://dx.doi.org/10.3389/fneur.2019.00746
_version_ 1783437585405706240
author Ortega-Gutierrez, Santiago
Lopez, Gloria V.
Edgell, Randall C.
Mendez, Aldo A.
Dandapat, Sudeepta
Roa, Jorge A.
Zevallos, Cynthia B.
Holcombe, Andrea L.
Hasan, David
Derdeyn, Colin P.
Rossen, James
Samaniego, Edgar A.
author_facet Ortega-Gutierrez, Santiago
Lopez, Gloria V.
Edgell, Randall C.
Mendez, Aldo A.
Dandapat, Sudeepta
Roa, Jorge A.
Zevallos, Cynthia B.
Holcombe, Andrea L.
Hasan, David
Derdeyn, Colin P.
Rossen, James
Samaniego, Edgar A.
author_sort Ortega-Gutierrez, Santiago
collection PubMed
description Objective: To report a single-center experience using drug-eluting balloon mounted stents (DES) for endovascular treatment of atherosclerotic ostial vertebral artery stenosis (OVAS). Background: Posterior circulation is affected in up to 25% of strokes, 20% of them resulting from atherosclerotic OVAS. The optimal management of symptomatic OVAS remains controversial. DES have been introduced to improve restenosis rates. Methods: We retrospectively analyzed prospectively collected data from patients with dominant OVAS who underwent endovascular treatment with second-generation DES placement. Patient demographics, clinical presentation, comorbidities, stenosis severity, stent features, technical success, complications, and imaging follow-up were assessed. Results: Thirty patients were treated, predominantly male (86.6%). Sixteen patients presented with an acute stroke or TIA and fourteen were treated on an elective basis due to symptomatic chronic stenosis and contralateral occlusion. Comorbidities included hyperlipidemia (83%), hypertension (70%) and prior stroke (63.3%). Mean ostial stenosis at presentation was 80 ± 14.8%. Twenty-one patients had contralateral VA involvement. DES deployment was technically successful in all patients using everolimus eluting stents in 30 lesions and zotarolimus eluting stents in two. One technical complication (stent migration) and three (10%) minor peri-procedural complications occurred. Complications included one asymptomatic ischemic infarct in the posterior circulation, one femoral artery thrombosis and one post-procedure altered mental status secondary to contrast induced neurotoxicity. Mean imaging follow-up was 8.8 months. Two (7.6%) patients had in-stent restenosis and underwent retreatment with angioplasty. There were no procedure-related mortalities. Conclusion: Our study confirms the feasibility of deploying DES for the treatment of ostial vertebral artery stenosis with low peri-procedural risk and low medium-term rates of re-stenosis.
format Online
Article
Text
id pubmed-6646661
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-66466612019-08-02 Second Generation Drug-Eluting Stents for Endovascular Treatment of Ostial Vertebral Artery Stenosis: A Single Center Experience Ortega-Gutierrez, Santiago Lopez, Gloria V. Edgell, Randall C. Mendez, Aldo A. Dandapat, Sudeepta Roa, Jorge A. Zevallos, Cynthia B. Holcombe, Andrea L. Hasan, David Derdeyn, Colin P. Rossen, James Samaniego, Edgar A. Front Neurol Neurology Objective: To report a single-center experience using drug-eluting balloon mounted stents (DES) for endovascular treatment of atherosclerotic ostial vertebral artery stenosis (OVAS). Background: Posterior circulation is affected in up to 25% of strokes, 20% of them resulting from atherosclerotic OVAS. The optimal management of symptomatic OVAS remains controversial. DES have been introduced to improve restenosis rates. Methods: We retrospectively analyzed prospectively collected data from patients with dominant OVAS who underwent endovascular treatment with second-generation DES placement. Patient demographics, clinical presentation, comorbidities, stenosis severity, stent features, technical success, complications, and imaging follow-up were assessed. Results: Thirty patients were treated, predominantly male (86.6%). Sixteen patients presented with an acute stroke or TIA and fourteen were treated on an elective basis due to symptomatic chronic stenosis and contralateral occlusion. Comorbidities included hyperlipidemia (83%), hypertension (70%) and prior stroke (63.3%). Mean ostial stenosis at presentation was 80 ± 14.8%. Twenty-one patients had contralateral VA involvement. DES deployment was technically successful in all patients using everolimus eluting stents in 30 lesions and zotarolimus eluting stents in two. One technical complication (stent migration) and three (10%) minor peri-procedural complications occurred. Complications included one asymptomatic ischemic infarct in the posterior circulation, one femoral artery thrombosis and one post-procedure altered mental status secondary to contrast induced neurotoxicity. Mean imaging follow-up was 8.8 months. Two (7.6%) patients had in-stent restenosis and underwent retreatment with angioplasty. There were no procedure-related mortalities. Conclusion: Our study confirms the feasibility of deploying DES for the treatment of ostial vertebral artery stenosis with low peri-procedural risk and low medium-term rates of re-stenosis. Frontiers Media S.A. 2019-07-16 /pmc/articles/PMC6646661/ /pubmed/31379708 http://dx.doi.org/10.3389/fneur.2019.00746 Text en Copyright © 2019 Ortega-Gutierrez, Lopez, Edgell, Mendez, Dandapat, Roa, Zevallos, Holcombe, Hasan, Derdeyn, Rossen and Samaniego. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Ortega-Gutierrez, Santiago
Lopez, Gloria V.
Edgell, Randall C.
Mendez, Aldo A.
Dandapat, Sudeepta
Roa, Jorge A.
Zevallos, Cynthia B.
Holcombe, Andrea L.
Hasan, David
Derdeyn, Colin P.
Rossen, James
Samaniego, Edgar A.
Second Generation Drug-Eluting Stents for Endovascular Treatment of Ostial Vertebral Artery Stenosis: A Single Center Experience
title Second Generation Drug-Eluting Stents for Endovascular Treatment of Ostial Vertebral Artery Stenosis: A Single Center Experience
title_full Second Generation Drug-Eluting Stents for Endovascular Treatment of Ostial Vertebral Artery Stenosis: A Single Center Experience
title_fullStr Second Generation Drug-Eluting Stents for Endovascular Treatment of Ostial Vertebral Artery Stenosis: A Single Center Experience
title_full_unstemmed Second Generation Drug-Eluting Stents for Endovascular Treatment of Ostial Vertebral Artery Stenosis: A Single Center Experience
title_short Second Generation Drug-Eluting Stents for Endovascular Treatment of Ostial Vertebral Artery Stenosis: A Single Center Experience
title_sort second generation drug-eluting stents for endovascular treatment of ostial vertebral artery stenosis: a single center experience
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6646661/
https://www.ncbi.nlm.nih.gov/pubmed/31379708
http://dx.doi.org/10.3389/fneur.2019.00746
work_keys_str_mv AT ortegagutierrezsantiago secondgenerationdrugelutingstentsforendovasculartreatmentofostialvertebralarterystenosisasinglecenterexperience
AT lopezgloriav secondgenerationdrugelutingstentsforendovasculartreatmentofostialvertebralarterystenosisasinglecenterexperience
AT edgellrandallc secondgenerationdrugelutingstentsforendovasculartreatmentofostialvertebralarterystenosisasinglecenterexperience
AT mendezaldoa secondgenerationdrugelutingstentsforendovasculartreatmentofostialvertebralarterystenosisasinglecenterexperience
AT dandapatsudeepta secondgenerationdrugelutingstentsforendovasculartreatmentofostialvertebralarterystenosisasinglecenterexperience
AT roajorgea secondgenerationdrugelutingstentsforendovasculartreatmentofostialvertebralarterystenosisasinglecenterexperience
AT zevalloscynthiab secondgenerationdrugelutingstentsforendovasculartreatmentofostialvertebralarterystenosisasinglecenterexperience
AT holcombeandreal secondgenerationdrugelutingstentsforendovasculartreatmentofostialvertebralarterystenosisasinglecenterexperience
AT hasandavid secondgenerationdrugelutingstentsforendovasculartreatmentofostialvertebralarterystenosisasinglecenterexperience
AT derdeyncolinp secondgenerationdrugelutingstentsforendovasculartreatmentofostialvertebralarterystenosisasinglecenterexperience
AT rossenjames secondgenerationdrugelutingstentsforendovasculartreatmentofostialvertebralarterystenosisasinglecenterexperience
AT samaniegoedgara secondgenerationdrugelutingstentsforendovasculartreatmentofostialvertebralarterystenosisasinglecenterexperience